| 1 |
20371722 | Potent preclinical impact of metronomic low-dose oral topotecan combined with the antiangiogenic drug pazopanib for the treatment of ovarian cancer. | 2010 Apr |
1 |
| 2 |
20935474 | Topotecan as a molecular targeting agent which blocks the Akt and VEGF cascade in platinum-resistant ovarian cancers. | 2010 Dec 1 |
3 |
| 3 |
19233938 | Use of an anti-vascular endothelial growth factor antibody in a pharmacokinetic strategy to increase the efficacy of intraperitoneal chemotherapy. | 2009 May |
7 |
| 4 |
19738426 | Anti-angiogenic properties of metronomic topotecan in ovarian carcinoma. | 2009 Aug |
1 |
| 5 |
18645007 | Topotecan inhibits vascular endothelial growth factor production and angiogenic activity induced by hypoxia in human neuroblastoma by targeting hypoxia-inducible factor-1alpha and -2alpha. | 2008 Jul |
5 |
| 6 |
17718196 | Antiproliferation in human EA.hy926 endothelial cells and inhibition of VEGF expression in PC-3 cells by topotecan. | 2007 Jul |
3 |
| 7 |
15895231 | Augmenting tumor sensitivity to topotecan by transient hypoxia. | 2005 Nov |
2 |
| 8 |
15930297 | Topotecan blocks hypoxia-inducible factor-1alpha and vascular endothelial growth factor expression induced by insulin-like growth factor-I in neuroblastoma cells. | 2005 Jun 1 |
1 |
| 9 |
11857382 | Topotecan inhibits VEGF- and bFGF-induced vascular endothelial cell migration via downregulation of the PI3K-Akt signaling pathway. | 2002 Mar 1 |
3 |